A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : BED / biologically effective dose

[Related PubMed/MEDLINE]
Total Number of Papers: 688
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BED  (>> Co-occurring Abbreviation)
Long Form:   biologically effective dose
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 A reinforcement learning approach for finding optimal policy of adaptive radiation therapy considering uncertain tumor biological response. ART, IQR, NSCLC, OARs, RL
2021 A Retrospective Registry Study Evaluating the Long-Term Efficacy and Safety of Superficial Radiation Therapy Following Excision of Keloid Scars. SRT
2021 Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: Feasibility and clinical outcomes. 3DCRT, HCC, IMRT, LC, OS, PVTT, RT, SBRT, VMAT
2021 Biological Effective Dose as a Predictor of Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis and Cohort Study of Patients Treated Using Contemporary Techniques. HR, IQR, SRS
2021 Biological Effective Dose for Treatment of a Heterogeneous Population of Cells with a Spread-Out Bragg Peak of Particle Radiation. SOBP
2021 Biologically effective dose correlates with linear tumor volume changes after upfront single-fraction stereotactic radiosurgery for vestibular schwannomas. GK, SRS, VSs
2021 Bone Density Changes Following Radiotherapy to Vertebral Metastases. BM, BMD, CT, Lyt, RT
2021 Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. AEs, CI, CRT, DM, EBC, HR, LP, LRP, OS, PFS, RT
2021 Classification of tolerable/intolerable mucosal toxicity of head-and-neck radiotherapy schedules with a biomathematical model of cell dynamics. EQD2, SEN, SPE
10  2021 Clinical and volumetric predictors of local control after robotic stereotactic radiosurgery for cerebral metastases: active systemic disease may affect local control in the brain. ---
11  2021 Combining computed tomography and biologically effective dose in radiomics and deep learning improves prediction of tumor response to robotic lung stereotactic body radiation therapy. AUC, CT, DL, DLCT,BED, ML, NSCLC, RadCT, RadCT,BED, SBRT
12  2021 Cumulative dose, toxicity, and outcomes of spinal metastases re-irradiation : Systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). AIRO, re-RT, SBRT
13  2021 Delta Radiomics Analysis for Local Control Prediction in Pancreatic Cancer Patients Treated Using Magnetic Resonance Guided Radiotherapy. GTV, LAPC, MRgRT, ROC
14  2021 Dosimetric comparison of intensity modulated radiotherapy and intensity modulated proton therapy in the treatment of recurrent nasopharyngeal carcinoma. CTV, ICA, IMPT, IMRT, NP, OARs, PTV, rNPC
15  2021 Effect of heterogeneous target dose and radiosensitivity on BED and TCP for different treatment regimens. Nf, SBRT, SRS, TCP
16  2021 Gamma Knife surgery for recurrent or persistent Cushing disease: long-term results and evaluation of biological effective dose in a series of 26 patients. SRS
17  2021 HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis. BRFS, CI, HDR-BRT-M
18  2021 Heuristic estimation of the α/β ratio for a cohort of Mexican patients with prostate cancer treated with external radiotherapy techniques. bRFS, OTT, PCa, RT
19  2021 Hippocampal Avoidance in Multitarget Radiosurgery. HD, IRB, MLCs, PTV, QoL, SD, SIMT, SRS, VMAT
20  2021 Impact of target dose inhomogeneity on BED and EUD in lung SBRT. EUD, PTV, SBRT
21  2021 Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. LCT, LRFS, NSCLC, OS, PFS, RT
22  2021 Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. A-RT, CI, OS, PDAC
23  2021 Long-term disease outcome and volume-based decision strategy in a large cohort of multiple brain metastases treated with a mono-isocentric linac-based Stereotactic Radiosurgery technique. BMs
24  2021 Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. mHSPC, OS, RT
25  2021 Merkel cell carcinoma: treatment and outcomes over a 10-year period at a high-volume academic center. AJCC, MCC, OS, RT
26  2021 MRI-guided radiotherapy for PVTT in HCC patients: evaluation of the efficacy and safety. HCC, HFRT, MRI, PVTT, SBRT
27  2021 MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach. HCC, MRgRT, RFA, RT, SBRT, TACE
28  2021 Multicomponent T2 relaxometry reveals early myelin white matter changes induced by proton radiation treatment. IEw, MW, MWI, PT
29  2021 Optimizing Whole Brain Radiotherapy Treatment and Dose for Patients With Brain Metastases From Small Cell Lung Cancer. BM, iPFS, OS, ROC, SCLC, WBRT
30  2021 Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. NENs, PD, RECIST, WD
31  2021 Palliative Radiation Therapy for Metastatic, Persistent, or Recurrent Epithelial Ovarian Cancer: Efficacy in the Era of Modern Technology and Targeted Agents. CNS, MPR-EOC, ORR, PRT, RT
32  2021 Population exposure-response model of 131I in patients with benign thyroid disease. Aa, ABD, MXR
33  2021 Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes. ADT, bPFS, DPFS, oligorPC, OS, PSA, SBRT
34  2021 Prostate cancer with nodular bladder invasion (stage T4N1) cured by low-dose-rate brachytherapy with seminal vesicle implantation in combination with external beam radiotherapy of biologically effective dose ≥ 220 Gy: a case report. ADT, EBRT, GI, GU, LDR, WP
35  2021 Quantitative assessments of late radiation-induced skin and soft tissue toxicity and correlation with RTOG scales and biological equivalent dose in breast cancer. RIT, RTOG
36  2021 Radiation Dose Rate, Biologically Effective Dose, and Tumor Characteristics on Local Control and Toxicity After Radiosurgery for Acoustic Neuromas. LF, SRS
37  2021 Radiation necrosis after a combination of external beam radiotherapy and iodine-125 brachytherapy in gliomas. EBRT, RN, SBT
38  2021 Radiobiological Evaluation of Combined Gamma Knife Radiosurgery and Hyperthermia for Pediatric Neuro-Oncology. HT, LQ, RT, TCP
39  2021 Radiobiological evaluation of organs at risk for electronic high-dose-rate brachytherapy in uveal melanoma: a radiobiological modeling study. 125I LDR-BT, EBT, HDR, LQ, OARs, USC, VR
40  2021 Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses. DPF, RT
41  2021 Stereotactic Body Radiation Therapy With a High Maximum Dose Improves Local Control, Cancer-Specific Death, and Overall Survival in Peripheral Early-Stage Non-Small Cell Lung Cancer. CI, CSD, ES-NSCLC, HR, OS, SBRT
42  2021 Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease. ILD, MLD, NSCLC, PFS, RILI, SBRT
43  2021 Stereotactic Inverse Dose Planning After Yttrium-90 Selective Internal Radiation Therapy in Hepatocellular Cancer. EBRT, EQD, HCC, SIRT
44  2021 Sublobar resection with intraoperative brachytherapy versus sublobar resection alone for early-stage non-small-cell lung cancer: a meta-analysis. CI, DFS, LR, RR, SR, SRB
45  2021 Synergy between early-incorporation immunotherapy and extracranial radiotherapy in metastatic non-small cell lung cancer. eIT, IT, mNSCLC, OS, RT, SBRT
46  2021 Technical Note: Break-even dose level for hypofractionated treatment schedules. LQ, LQ-L, NT
47  2021 Ten-step method of high-dose LDR 125 I brachytherapy for intermediate-risk prostate cancer. LDR, UIR
48  2021 The impact of unscheduled gaps and iso-centre sequencing on the biologically effective dose in Gamma Knife radiosurgery. GK
49  2021 The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases. HSRT, LMD, RN, SRS
50  2021 The Role of Biological Effective Dose in Predicting Obliteration After Stereotactic Radiosurgery of Cerebral Arteriovenous Malformations. AVMs, CI, HR, IQR, MRI, SRS
51  2021 Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas. mALBI, OS
52  2021 Tumor Control Probability Modeling for Radiation Therapy of Keratinocyte Carcinoma. KC, RT, TCP
53  2021 Ultra hypofractionated extended nodal irradiation using volumetric modulated arc therapy for oligorecurrent pelvic nodal prostate cancer. ENI, GTVn, NTCP, OARs, PCa, PTVn, SABR, SIB, TCP, VMAT
54  2020 A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery for the treatment of brain metastasis. HF-SRS, SF-SRS
55  2020 A single-institutional experience with low dose stereotactic body radiation therapy for liver metastases. GTV, OS, SBRT
56  2020 A theoretical cell-killing model to evaluate oxygen enhancement ratios at DNA damage and cell survival endpoints in radiation therapy. OER, OERDSB
57  2020 Adjuvant Chemotherapy and Dose Escalation in Definitive Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. dCCRT, ESCC, LRFS, OS
58  2020 Adoption of Biologically Effective Dose of the Non-Target Lung Volume to Predict Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy With Variable Fractionations for Lung Cancer. ROC, SBRT, SRP
59  2020 Analysis of cardiac toxicity after definitive chemoradiotherapy for esophageal cancer using a biological dose-volume histogram. CRT, DVH, OARs, PE
60  2020 Assessment of biological dosimetric margin for stereotactic body radiation therapy. AP, BCF, BDM, CC, DPF, LR, PD, PDM, SBRT
61  2020 Association between IDO activity and prognosis in patients with non-small cell lung cancer after radiotherapy. IDO, KYN, NSCLC, RT, Trp
62  2020 Biologically effective dose (BED) escalation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma patients (≤5 cm) with CyberKnife: protocol of study. ICGR15, LC, OS, PFS, PLA, RILD, SBRT
63  2020 Biologically effective dose and prediction of obliteration of unruptured arteriovenous malformations treated by upfront Gamma Knife radiosurgery: a series of 149 consecutive cases. AVMs, GKRS
64  2020 Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer. ADT, BFFS, CSS, EBRT, FFCF, LDR, OS
65  2020 Developing a Mobile Phone Application for Common Radiotherapy Calculations. TDF
66  2020 Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. D0.1cm3, D1cm3, GTV, LC, PTV, SBRT, V5Gy
67  2020 Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study. FFLP, HCC, OS, PSM, SBRT
68  2020 Dosimetric comparison between RapidArc and HyperArc techniques in salvage stereotactic body radiation therapy for recurrent nasopharyngeal carcinoma. HA, NPC, OARs, RA, SBRT, VMAT
69  2020 Effect of hypofractionation on the incidental axilla dose during tangential field radiotherapy in breast cancer. SLNB, TCP
70  2020 Electron Density and Biologically Effective Dose (BED) Radiomics-Based Machine Learning Models to Predict Late Radiation-Induced Subcutaneous Fibrosis. 3D-BED, AUC, CTAE, EML, HU, ML, NB, PBI, PTV, RIF, SVM
71  2020 Evaluating the biologically effective dose (BED) concept using a dynamic tumor simulation model. ---
72  2020 Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma. CSI, DFI, EQD2, IQR, OS, PFS, re-RT
73  2020 External Validation of Early Regression Index (ERITCP) as Predictor of Pathologic Complete Response in Rectal Cancer Using Magnetic Resonance-Guided Radiation Therapy. MR, pCR, TCP
74  2020 Four-year follow-up outcomes after stereotactic body radiation therapy for central early-stage non-small cell lung cancer. IMRT, NSCLC, OS, PFS, PTV, SBRT
75  2020 FSRT vs. SRS in Brain Metastases-Differences in Local Control and Radiation Necrosis-A Volumetric Study. FSRT, SRS
76  2020 Gamma Knife radiosurgery for acromegaly: Evaluating the role of the biological effective dose associated with endocrine remission in a series of 42 consecutive cases. GH, PA, SRS
77  2020 Generalized Multi-Hit Model of Radiation-Induced Cell Survival with a Closed-Form Solution: An Alternative Method for Determining Isoeffect Doses in Practical Radiotherapy. LET, LQ, LQL, PTV, SBRT
78  2020 High Biologically Effective Dose Radiotherapy for Brain Metastases May Improve Survival and Decrease Risk for Local Relapse Among Patients With Small-Cell Lung Cancer: A Propensity-Matching Analysis. BM-PFS, BMs, OS, PS, SCLC
79  2020 Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group. HCC, ICC, LC, PBT
80  2020 Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience. LCR, OS, PFS
81  2020 I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes. CSS, FFBF, FFMs, HRPC, PSA
82  2020 Integrin αvβ6 Positron Emission Tomography Imaging in Lung Cancer Patients Treated With Pulmonary Radiation Therapy. PET, RT
83  2020 Intensity-modulated radiation therapy administered to a previously irradiated spine is effective and well-tolerated. IMRT
84  2020 Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation. CSS, EBRT, FBF, GG, PSA
85  2020 Myths, facts and scope of spinal cord tolerance dose revision in Intensity modulated SIB treatment of locally advanced head and neck cancer: A dosimetrical and radiobiological demonstration. OAR, OARs, PRV, SIB, SPDE, TCP, WoO
86  2020 Palliative radiotherapy for gastric cancer: Is there a dose relationship between bleeding response and radiotherapy? CI, GC, RT
87  2020 Partial prostate re-irradiation for the treatment of isolated local recurrence of prostate cancer in patients previously treated with primary external beam radiotherapy: short-term results of a monocentric study. EBRT, GI, GU, PCa, PPR
88  2020 Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients. HR, OS, SBRT
89  2020 Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia. ---
90  2020 Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists. ICIs, LQ, SABR, TCP
91  2020 Radiotherapy for the prophylaxis of heterotopic ossification after total hip arthroplasty: A systematic review and meta-analysis of randomized controlled trails. HO, THA
92  2020 Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. FRT, LC, MMT, MPM, TFST
93  2020 Significant Correlation Between Overall Survival and Mean Lung Dose in Lung Stereotactic Body Radiation Therapy (SBRT). FEV1, IDL, LC, NSCLC, OS, SBRT, VMAT
94  2020 Single-fraction radiosurgery versus fractionated stereotactic radiotherapy in patients with brain metastases: a comparative study. HFSRT, LC, RN, SRS
95  2020 Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience. LC, OS, SSRS
96  2020 Stereotactic body radiation therapy for empirically treated hypermetabolic lung lesions: a single-institutional experience identifying the Charlson score as a key prognostic factor. NSCLC, OS, PET, SBRT, SUV
97  2020 Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations. CCI, CSS, ES-NSCLC, fr, LC, PTV, SBRT
98  2020 Stereotactic Body Radiation Therapy for Salvage Treatment of Recurrent Non-Small Cell Lung Cancer. EBRT, NSCLC, PFS, SBRT
99  2020 Stereotactic body radiation therapy in the treatment of ovarian cancer. HR, OS, PFS, SBRT
100  2020 Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. BTC, DPFS, LC, mBTC, OS, SBRT